Telmisartan市场：按成分、按适应症、按剂型、按分销管道、按地区

预计2024年Telmisartan的全球市场规模为42亿美元，预计2031年将达到54.1亿美元，2024年至2031年的复合年增长率为3.7%。

图：2024 年Telmisartan市场占有率（%），依地区划分

Telmisartan是一种血管收缩素II 受体拮抗剂，主要用于治疗高血压和糖尿病肾臟病。它的作用是选择性抑制血管收缩素II 与血管平滑肌和肾上腺中存在的 AT1 受体的结合。Telmisartan可透过抑制血管收缩素II的血管收缩和醛固酮分泌作用来降低血压。Telmisartan以多种品牌作为口服药物出售，其安全性已通过长期临床试验得到证实。人们对心血管健康意识的提高和高血压盛行率的增加可能会推动全球Telmisartan市场的成长。

市场动态：

人口快速老化、全球高血压盛行率上升、肥胖导致的久坐生活方式增加以及新兴国家医疗保健支出增加等因素推动了Telmisartan的全球市场成长。然而，学名药替代的潜力和主要品牌的专利到期可能会给市场相关人员带来挑战。扩大Telmisartan治疗用途的持续研究以及评估其治疗高血压以外疾病功效的正在进行的临床试验可能会在不久的将来为相关人员提供机会。与开发中国家的当地分销网络合作​​也是挖掘未满足需求的一种有吸引力的方式。

本研究的主要特点

• 本报告对全球Telmisartan市场进行了详细分析，并提出了以2023年为基准年的预测期（2024-2031）的市场规模和年复合成长率（CAGR%）。
• 它还揭示了各个细分市场的潜在商机，并说明了该市场有吸引力的投资提案矩阵。
• 它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的主要考察。
• 它包括基于公司亮点、产品系列、主要亮点、业绩和策略等参数的全球Telmisartan市场主要企业的概况。
• 该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
• 全球Telmisartan市场报告针对该行业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
• 透过用于全球Telmisartan市场分析的各种策略矩阵，将促进相关人员的决策。

目录

第一章 研究目的与前提

• 研究目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要
• 一致的机会地图 (COM)

第三章 市场动态、法规与趋势分析

• 市场动态
  • 促进因素
  • 抑制因素
  • 机会
• 影响分析
• 市场趋势
• 监管场景
• 收购和合作场景
• 资金筹措和投资
• PEST分析
• 波特的分析

第四章全球Telmisartan市场－冠状病毒（COVID-19）大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第五章全球Telmisartan市场，依构成，2019-2031（十亿美元）

• 介绍
• 单身的
• 混合物

第六章Telmisartan全球市场，依指标划分，2019-2031 年（十亿美元）

• 介绍
• 高血压
• 肾臟病
• 肝肾症候群
• 心臟麻痹
• 中风

第七章Telmisartan全球市场，按剂型，2019-2031（十亿美元）

• 介绍
• 锭剂
• 胶囊
• 注射
• 口服混悬剂

第8章全球Telmisartan市场，依通路，2019-2031（十亿美元）

• 介绍
• 医院药房
• 零售药房
• 网路药房

第9章2019-2031年全球Telmisartan市场（按地区）（十亿美元）

• 介绍
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东

第10章竞争格局

• 公司简介
  • Boehringer Ingelheim GmbH
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Mylan NV
  • Cipla Ltd.
  • Abbott Laboratories
  • Cadila Healthcare Ltd
  • Torrent Pharmaceuticals Ltd.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi SA
  • Bayer AG
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Macleods Pharmaceuticals Ltd.

第十一章分析师建议

• 上升和下降
• 综合机会图

第十二章参考文献与调查方法

• 参考
• 调查方法

Global telmisartan market is estimated to be valued at USD 4.20 Bn in 2024 and is expected to reach USD 5.41 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 3.7% from 2024 to 2031.

Figure. Telmisartan Market Share (%), By Region 2024

Telmisartan is an angiotensin II receptor antagonist that is used primarily in the treatment of hypertension and diabetic nephropathy. It works by selectively blocking the binding of angiotensin II to the AT1 receptors present in vascular smooth muscle and the adrenal glands. By blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II, telmisartan helps lower blood pressure. It is available under various brand names as an oral medication and has a well-established safety profile supported by long-term clinical trials. Growing awareness about cardiovascular health and increasing prevalence of hypertension can drive the global telmisartan market growth.

Market Dynamics:

Global telmisartan market growth is driven by factors such as rapidly aging population, rising prevalence of hypertension worldwide, increasing adoption of sedentary lifestyle resulting in obesity, and growing healthcare expenditure in emerging nations. However, availability of generic substitutes and patent expiration of major brands can pose challenges for market players. Continuous research on expanding therapeutic applications of telmisartan and ongoing clinical trials evaluating its efficacy in treatment of conditions beyond hypertension can offer opportunities for stakeholders in the near future. Partnerships with local distribution networks in developing countries also provide an attractive avenue for leveraging unmet demand.

Key Features of the Study:

• This report provides in-depth analysis of the global telmisartan market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global telmisartan market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include, Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Abbott Laboratories, Cadila Healthcare Ltd, Torrent Pharmaceuticals Ltd., Merck KGaA, Pfizer Inc., Sanofi S.A., Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Macleods Pharmaceuticals Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global telmisartan market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global telmisartan market

Detailed Segmentation-

• By Composition
  • Single
  • Combinational
• By Indication
  • Hypertension
  • Nephropathy
  • Hepatorenal Syndrome
  • Cardiac Arrest
  • Stroke
• By Dosage Form
  • Tablets
  • Capsules
  • Injection
  • Oral suspension
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Boehringer Ingelheim GmbH
  • Glenmark Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Cipla Ltd.
  • Abbott Laboratories
  • Cadila Healthcare Ltd
  • Torrent Pharmaceuticals Ltd.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi S.A.
  • Bayer AG
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Macleods Pharmaceuticals Ltd.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Composition
  • Market Snapshot, By Indication
  • Market Snapshot, By Dosage Form
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Telmisartan Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Telmisartan Market, By Composition, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Single
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Combinational
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Telmisartan Market, By Indication 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hypertension
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Nephropathy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Hepatorenal Syndrome
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Cardiac Arrest
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Stroke
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Telmisartan Market, By Dosage Form, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Tablets
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Capsules
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Injection
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Oral suspension
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Telmisartan Market, By Distribution Channel 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Telmisartan Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Composition, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage Form 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Company Profiles
  • Boehringer Ingelheim GmbH
    • Company Highlights
    • Composition Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Glenmark Pharmaceuticals Ltd.
    • Company Highlights
    • Composition Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Composition Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sandoz International GmbH
    • Company Highlights
    • Composition Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Cipla Ltd.
  • Abbott Laboratories
  • Cadila Healthcare Ltd
  • Torrent Pharmaceuticals Ltd.
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi S.A.
  • Bayer AG
  • AstraZeneca PLC
  • Daiichi Sankyo Company, Limited
  • Macleods Pharmaceuticals Ltd.

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact